RE: Clinical validation not started......?2 Sep 2020 08:12
In fairness, AS stated in his last interview that shareholders would be updated as each milestone in the process is achieved. Presumably one of these will be when the pilot batches have been manufactured? Then when clinical validation begins, like with BAMS?
I was thinking along similar lines. In the latest directors talk interview, AS mentions all of the key milestones (pilot batches created etc) and infers that the market will be updated as each of these is met.
I guess this could have changed though. Especially if the government are involved, and want less transparency.
In that case, it's not an option for Cytiva to have manufactured pilot batches of the completed product, and submitted them for EUA then, in your opinion?
Appreciate that. I am invested, albeit modestly. Love reading this board and have picked up some great info along the way.
@Richrob, I think that you’re one of the most informative posters on this board, and seem a genuinely nice person as well. I hope I haven’t made it to the green bin yet.
Apologies all. I genuinely didn’t intend to clog up the board with a childish spat. Just wanted clarification on a few points :-) I’ll pop back in my hole and make sure I attempt to discover the info for myself before asking a seeking such clarification again.
I’ve always had you down as a top poster, and appreciated you sharing your knowledge on this BB. Also questioned some posters attitude towards you. Now I fully understand it. You really are a condescending fool.
I was merely after a bit of clarification from somebody like yourself. I'm not sure the condescending feel to your first sentence was entirely required, but there you go.
‘These Affimer reagents will be characterised by Avacta with the aim of developing a laboratory test for the SARS-COV-2 virus antigen within the next few weeks.’